Contrary to the decade-long trend of outsourcing to CDMOs, major pharmaceutical companies are now vertically re-integrating their supply chains. Driven by supply chain vulnerabilities, they now view manufacturing not as a cost center but as a strategic advantage, creating opportunities for technology enablers rather than just capacity providers.

The conventional wisdom for CPG startups was to be "asset-light" and use co-packers. However, owning the supply chain provides crucial control over quality, production schedules, and cash flow, preventing startups from being pushed aside by a co-packer's larger clients. This control is now a key diligence point.

Relying on a traditional supply chain means inheriting its slow pace, costs, and outdated technology. By bringing core manufacturing in-house, Tesla controls its innovation speed, allowing it to move much faster and develop more integrated products than its competitors.

In the biosimilars industry, where prices inevitably decline over time, full vertical integration (from R&D to commercialization) is essential for survival. By controlling the entire value chain, companies like Biocon avoid profit-sharing with partners, preserving margins and enabling them to withstand market pressures that would cripple less integrated competitors.

A frozen fry company built its own facility to control its unique process using beef tallow. This vertical integration ensures quality and creates a secondary revenue stream by wholesaling to other restaurants, described as a "sneaky wholesale business."

If your business relies on third-party suppliers for deals (e.g., real estate wholesalers), the fastest way to grow is to acquire one. Your superior monetization model allows you to extract more value from their operation, giving you control over the entire supply chain.

Unlike competitors focused on "shaving pennies," Peter Thomas Roth's vertical integration (owning R&D and manufacturing) provides a key advantage. This allows them to incorporate more expensive, effective ingredients without conglomerate pressure, maintaining a commitment to product perfection and giving them a significant leg up in a competitive market.

A key competitive advantage for cocktail brand Buzz Balls was owning its supply chain. The founder brought the production of both the patented spherical plastic containers and the spirits in-house. This strategic move ensured quality and reliability, a challenge where most D2C founders fail by remaining dependent on co-packers.

Figure designs nearly every component of its robots in-house, from motors to batteries. This extreme vertical integration, though costly upfront, prevents being at the mercy of third-party vendor timelines, code problems, or supply chain issues, enabling faster iteration and deeper system control.